Silicane Derivative Increases Doxorubicin Efficacy in an
Ovarian Carcinoma Mouse Model: Fighting Drug Resistance

J 2021

Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance

FOJTŮ, Michaela; Jan BALVAN; Tomáš VIČAR; Hana HOLCOVÁ POLANSKÁ; Barbora PELTANOVÁ et. al.

Základní údaje

Originální název

Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance

Autoři

Vydání

ACS APPLIED MATERIALS & INTERFACES, WASHINGTON, AMER CHEMICAL SOC, 2021, 1944-8244

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

21001 Nano-materials

Stát vydavatele

Spojené státy

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 10.383

Kód RIV

RIV/00216224:14110/21:00120131

Organizační jednotka

Lékařská fakulta

DOI

https://doi.org/10.1021/acsami.0c20458

UT WoS

000674333400004

EID Scopus

2-s2.0-85110987311

Klíčová slova anglicky

2D nanomaterials; silicene; polysiloxane; nanosheets; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance

Štítky

14110515, 14110518, CF CELLIM, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 13. 5. 2025 13:03, Mgr. Tereza Miškechová

Anotace

V originále

The development of cancer resistance continues to represent a bottleneck of cancer therapy. It is one of the leading factors preventing drugs to exhibit their full therapeutic potential. Consequently, it reduces the efficacy of anticancer therapy and causes the survival rate of therapy-resistant patients to be far from satisfactory. Here, an emerging strategy for overcoming drug resistance is proposed employing a novel two-dimensional (2D) nanomaterial polysiloxane (PSX). We have reported on the synthesis of PSX nanosheets (PSX NSs) and proved that they have favorable properties for biomedical applications. PSX NSs evinced unprecedented cytocompatibility up to the concentration of 300 mu g/mL, while inducing very low level of red blood cell hemolysis and were found to be highly effective for anticancer drug binding. PSX NSs enhanced the efficacy of the anticancer drug doxorubicin (DOX) by around 27.8-43.4% on average and, interestingly, were found to be especially effective in the therapy of drug-resistant tumors, improving the effectiveness of up to 52%. Fluorescence microscopy revealed improved retention of DOX within the drug-resistant cells when bound on PSX NSs. DOX bound on the surface of PSX NSs, i.e., PSX@DOX, improved, in general, the DOX cytotoxicity in vitro. More importantly, PSX@DOX reduced the growth of DOX-resistant tumors in vivo with 3.5 times better average efficiency than the free drug. Altogether, this paper represents an introduction of a new 2D nanomaterial derived from silicane and pioneers its biomedical application. As advances in the field of material synthesis are rapidly progressing, novel 2D nanomaterials with improved properties are being synthesized and await thorough exploration. Our findings further provide a better understanding of the mechanisms involved in the cancer resistance and can promote the development of a precise cancer therapy.

Návaznosti

MUNI/A/1246/2020, interní kód MU

Název: Kardiovaskulární systém: od iontového kanálu k celotělovému modelu (Akronym: KAVASYKAMO)

Investor: Masarykova univerzita, Kardiovaskulární systém: od iontového kanálu k celotělovému modelu

MUNI/A/1698/2020, interní kód MU

Název: Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí (Akronym: ComplexPF)

Investor: Masarykova univerzita, Od molekulární, buněčné a tkáňové k systémové patofyziologii vybraných komplexních nemocí

NU21-08-00407, projekt VaV

Název: Funkční nanoroboti pro navigovanou kombinovanou nádorovou terapii

Investor: Ministerstvo zdravotnictví ČR, Funkční nanoroboti pro navigovanou kombinovanou nádorovou terapii, Podprogram 1 - standardní

ROZV/28/LF17/2020, interní kód MU

Název: Magnetoboti pro fototermální a magnetotermální terapii nádorových onemocnění

Investor: Ministerstvo školství, mládeže a tělovýchovy ČR, Magnetoboti pro fototermální a magnetotermální terapii nádorových onemocnění, Interní rozvojové projekty

90129, velká výzkumná infrastruktura

Název: Czech-BioImaging II

Citovat

FOJTŮ, Michaela; Jan BALVAN; Tomáš VIČAR; Hana HOLCOVÁ POLANSKÁ; Barbora PELTANOVÁ; Stanislava MATEJKOVA; Martina RAUDENSKÁ; Jiri STURALA; Paula MAYORGA-BURREZO; Michal MASAŘÍK a Martin PUMERA. Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance. ACS APPLIED MATERIALS & INTERFACES. WASHINGTON: AMER CHEMICAL SOC, 2021, roč. 13, č. 27, s. 31355-31370. ISSN 1944-8244. Dostupné z: https://doi.org/10.1021/acsami.0c20458.

@article{1787479,
   author = {Fojtů, Michaela and Balvan, Jan and Vičar, Tomáš and Holcová Polanská, Hana and Peltanová, Barbora and Matejkova, Stanislava and Raudenská, Martina and Sturala, Jiri and MayorgaandBurrezo, Paula and Masařík, Michal and Pumera, Martin},
   article_location = {WASHINGTON},
   article_number = {27},
   doi = {https://doi.org/10.1021/acsami.0c20458},
   keywords = {2D nanomaterials; silicene; polysiloxane; nanosheets; targeted drug delivery; doxorubicin; ovarian cancer; drug resistance},
   language = {eng},
   issn = {1944-8244},
   journal = {ACS APPLIED MATERIALS & INTERFACES},
   title = {Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance},
   url = {https://pubs.acs.org/doi/10.1021/acsami.0c20458},
   volume = {13},
   year = {2021}
}

TY  - JOUR
ID  - 1787479
AU  - Fojtů, Michaela - Balvan, Jan - Vičar, Tomáš - Holcová Polanská, Hana - Peltanová, Barbora - Matejkova, Stanislava - Raudenská, Martina - Sturala, Jiri - Mayorga-Burrezo, Paula - Masařík, Michal - Pumera, Martin
PY  - 2021
TI  - Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance
JF  - ACS APPLIED MATERIALS & INTERFACES
VL  - 13
IS  - 27
SP  - 31355-31370
EP  - 31355-31370
PB  - AMER CHEMICAL SOC
SN  - 19448244
KW  - 2D nanomaterials
KW  - silicene
KW  - polysiloxane
KW  - nanosheets
KW  - targeted drug delivery
KW  - doxorubicin
KW  - ovarian cancer
KW  - drug resistance
UR  - https://pubs.acs.org/doi/10.1021/acsami.0c20458
N2  - The development of cancer resistance continues to represent a bottleneck of cancer therapy. It is one of the leading factors preventing drugs to exhibit their full therapeutic potential. Consequently, it reduces the efficacy of anticancer therapy and causes the survival rate of therapy-resistant patients to be far from satisfactory. Here, an emerging strategy for overcoming drug resistance is proposed employing a novel two-dimensional (2D) nanomaterial polysiloxane (PSX). We have reported on the synthesis of PSX nanosheets (PSX NSs) and proved that they have favorable properties for biomedical applications. PSX NSs evinced unprecedented cytocompatibility up to the concentration of 300 mu g/mL, while inducing very low level of red blood cell hemolysis and were found to be highly effective for anticancer drug binding. PSX NSs enhanced the efficacy of the anticancer drug doxorubicin (DOX) by around 27.8-43.4% on average and, interestingly, were found to be especially effective in the therapy of drug-resistant tumors, improving the effectiveness of up to 52%. Fluorescence microscopy revealed improved retention of DOX within the drug-resistant cells when bound on PSX NSs. DOX bound on the surface of PSX NSs, i.e., PSX@DOX, improved, in general, the DOX cytotoxicity in vitro. More importantly, PSX@DOX reduced the growth of DOX-resistant tumors in vivo with 3.5 times better average efficiency than the free drug. Altogether, this paper represents an introduction of a new 2D nanomaterial derived from silicane and pioneers its biomedical application. As advances in the field of material synthesis are rapidly progressing, novel 2D nanomaterials with improved properties are being synthesized and await thorough exploration. Our findings further provide a better understanding of the mechanisms involved in the cancer resistance and can promote the development of a precise cancer therapy.
ER  -

FOJTŮ, Michaela; Jan BALVAN; Tomáš VIČAR; Hana HOLCOVÁ POLANSKÁ; Barbora PELTANOVÁ; Stanislava MATEJKOVA; Martina RAUDENSKÁ; Jiri STURALA; Paula MAYORGA-BURREZO; Michal MASAŘÍK a Martin PUMERA. Silicane Derivative Increases Doxorubicin Efficacy in an Ovarian Carcinoma Mouse Model: Fighting Drug Resistance. \textit{ACS APPLIED MATERIALS \&{} INTERFACES}. WASHINGTON: AMER CHEMICAL SOC, 2021, roč.~13, č.~27, s.~31355-31370. ISSN~1944-8244. Dostupné z: https://doi.org/10.1021/acsami.0c20458.

Přehled o publikaci